EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

Michael J Ellis, Christiana Lekka, Katie L Holden, Hanna Tulmin, Faheem Seedat, Darragh P O'Brien, Shalinee Dhayal, Marie-Louise Zeissler, Jakob G Knudsen, Benedikt M Kessler, Noel G Morgan, John A Todd und 2 weitere

Acta Neuropathologica · 2024-06 · 147 (1)

DOI: 10.1007/s00401-024-02729-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 18.05.2024. Verfasst von Michael J Ellis und 13 weiteren Autor:innen. Beteiligte Einrichtung: JDRF/Wellcome Diabetes and Inflammation Laboratory, Nuffield Department of Medicine, Centre for Human Genetics, University of Oxford, Roosevelt Drive…. Hauptthemen laut MEDLINE: tau Proteins, Immunohistochemistry, Antibodies, Blotting, Western. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Juvenile Diabetes Research Foundation International, Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies are essential research tools whose performance directly impacts research conclusions and reproducibility. Owing to its central role in Alzheimer’s disease and other dementias, hundreds of distinct antibody clones have been developed against the microtubule-associated protein Tau and its multiple proteoforms. Despite this breadth of offer, limited understanding of their performance and poor antibody selectivity have hindered research progress. Here, we validate a large panel of Tau antibodies by Western blot (79 reagents) and immunohistochemistry (35 reagents). We address the reagents’ ability to detect the target proteoform, selectivity, the impact of protein phosphorylation on antibody binding and performance in human brain samples. While most antibodies detected Tau at high levels, many failed to detect it at lower, endogenous levels. By WB, non-selective binding to other proteins affected over half of the antibodies tested, with several cross-reacting with the related MAP2 protein, whereas the “oligomeric Tau” T22 antibody reacted with monomeric Tau by WB, thus calling into question its specificity to Tau oligomers. Despite the presumption that “total” Tau antibodies are agnostic to post-translational modifications, we found that phosphorylation partially inhibits binding for many such antibodies, including the popular Tau-5 clone. We further combine high-sensitivity reagents, mass-spectrometry proteomics and cDNA sequencing to demonstrate that presumptive Tau “knockout” human cells continue to express residual protein arising through exon skipping, providing evidence of previously unappreciated gene plasticity. Finally, probing of human brain samples with a large panel of antibodies revealed the presence of C-term-truncated versions of all main Tau brain isoforms in both control and tauopathy donors. Ultimately, we identify a validated panel of Tau antibodies that can be employed in Western blotting and/or immunohistochemistry to reliably detect even low levels of Tau expression with high selectivity. This work represents an extensive resource that will enable the re-interpretation of published data, improve reproducibility in Tau research, and overall accelerate scientific progress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsImmunohistochemistryAntibodiesBlotting, WesternBrainHumansPhosphorylationAlzheimer DiseaseReproducibility of Results

Stichwörter der Autor:innen

Antibody validationImmunohistochemistryPhosphorylationSplice isoformsTauWestern blot

Substanzen

tau ProteinsAntibodiesMAPT protein, human

Autor:innen und Institutionen

  • JDRF/Wellcome Diabetes and Inflammation Laboratory, Nuffield Department of Medicine, Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, UK.
  • Islet Biology Group, Department of Clinical & Biomedical Sciences, Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter, RILD Building, Exeter, UK.
  • Nuffield Department of Women's and Reproductive Health, Women's Centre, University of Oxford, John Radcliffe Hospital, Level 3, Oxford, UK.
  • Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, UK.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Oxford, Radcliffe, UK.
  • Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: M Irina Stefana

Förderung

  • Juvenile Diabetes Research Foundation International
  • Wellcome Trust
  • Medical Research Council
  • Research England
  • UCB Biopharma

Zitieren

APA

Ellis, M. J., Lekka, C., Holden, K. L., Tulmin, H., Seedat, F., O'Brien, D. P., Dhayal, S., Zeissler, M. L., Knudsen, J. G., Kessler, B. M., Morgan, N. G., Todd, J. A., Richardson, S. J., & Stefana, M. I. (2024). Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02729-7

Vancouver

Ellis MJ, Lekka C, Holden KL, Tulmin H, Seedat F, O'Brien DP, et al. Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-024-02729-7

BibTeX
@article{Ellis2024,
  author = {Ellis, Michael J and Lekka, Christiana and Holden, Katie L and Tulmin, Hanna and Seedat, Faheem and O'Brien, Darragh P and Dhayal, Shalinee and Zeissler, Marie-Louise and Knudsen, Jakob G and Kessler, Benedikt M and Morgan, Noel G and Todd, John A and Richardson, Sarah J and Stefana, M Irina},
  title = {Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry},
  journal = {Acta Neuropathologica},
  year = {2024},
  volume = {147},
  number = {1},
  doi = {10.1007/s00401-024-02729-7}
}
Kostenlos starten →